• Corpus ID: 10793898

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.

@article{Boissier2000BisphosphonatesIB,
  title={Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.},
  author={Sandrine Boissier and Mercedes Ferreras and Olivier Peyruchaud and S Magnetto and Frank H. Ebetino and Marc Colombel and Pierre Dominique Delmas and Jean-Marie Delaiss{\'e} and Philippe Cl{\'e}zardin},
  journal={Cancer research},
  year={2000},
  volume={60 11},
  pages={
          2949-54
        }
}
The molecular mechanisms by which tumor cells metastasize to bone are likely to involve invasion, cell adhesion to bone, and the release of soluble mediators from tumor cells that stimulate osteoclast-mediated bone resorption. Bisphosphonates (BPs) are powerful inhibitors of the osteoclast activity and are, therefore, used in the treatment of patients with osteolytic metastases. However, an added beneficial effect of BPs may be direct antitumor activity. We previously reported that BPs inhibit… 

Figures from this paper

How do bisphosphonates inhibit bone metastasis in vivo?
TLDR
Risedronate did inhibit B02 breast cancer bone metastasis formation by reducing both bone destruction and skeletal tumor burden, indicating that the antitumor effect of bisphosphonates is achieved mainly through inhibition of osteoclast-mediated bone resorption.
Mechanisms of Bisphosphonate Effects on Osteoclasts, Tumor Cell Growth, and Metastasis
TLDR
In vitro evidence that bisphosphonates inhibit proliferation and induce apoptosis of tumor cell lines and short-circuit intracellular signaling via small guanine triphosphatases, such as Ras, are supported by a growing body of evidence from animal models demonstrating that bis phosphonate can reduce skeletal tumor burden.
Bisphosphonate treatment inhibits the growth of prostate cancer cells.
TLDR
The intriguing possibility that the observed clinical utility of bisphosphonates in managing skeletal metastases may in part derive from direct inhibition of prostate cancer cell growth in the bone microenvironment is raised.
Bisphosphonate Actions on Cancer
TLDR
With currently available clinical and in vivo experimental data, BPs are definitely beneficial for the treatment of cancer patients who manifest clinically detectable bone metastases, however, it is not recommended that BP be given as a preventative to patients with visceral metastases and of no evidence of bone metastase.
Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
TLDR
Pre-clinical and clinical evidence suggest that potent BPs have direct and/or indirect anti-tumor effects, through induction of apoptosis, inhibition of invasion and metastases as well as angiogenesis, and through alteration of the immune system.
Bisphosphonates in breast cancer: clinical activity and implications of preclinical data.
  • R. Aft
  • Biology, Medicine
    Clinical advances in hematology & oncology : H&O
  • 2011
TLDR
In addition to reducing the risk of breast cancer, bisphosphonate therapy has been shown to improve outcomes of early and metastatic breast cancer treatment.
Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway.
TLDR
It is suggested that interference with this pathway is involved in inhibition of invasion and migration of prostate cancer cells by the amino-BP alendronate but that the mechanism of clodronate inhibition is different, and it is possible that BPs have therapeutic potential in preventing the spread of prostatecancer.
Bisphosphonates in cancer therapy
TLDR
A growing body of evidence from animal models demonstrating that bisphosphonates can reduce skeletal tumor burden is supported, however, it remains unclear whether this reduction reflects a direct antitumor effect or an indirect effect via osteoclast inhibition and alteration of the bone microenvironment.
Potential anticancer properties of bisphosphonates.
TLDR
Whether bisphosphonates given early in the course of cancer will be able to prevent formation of metastases, in or out of the bone environment is established.
Ibandronate in metastatic bone disease: a review of preclinical data
TLDR
Preclinical evidence supports the rationale for adjuvant treatment with ibandronate for patients at risk of metastatic bone disease and the renal safety profile of ib andronate supports its suitability for long-term adjUvant use, even with intermittent high dosing.
...
...

References

SHOWING 1-10 OF 25 REFERENCES
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
TLDR
Evidence is provided for a direct cellular effect of BP in preventing tumor cell adhesion to bone, suggesting that BPs may be useful agents for the prophylactic treatment of patients with cancer that is known to preferentially metastasize to bone.
Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
TLDR
Inhibition of both MMPs and osteoclastic bone resorption are more efficacious treatment for prevention of osteolytic lesions than either alone, and suggest that when therapies are designed based on the uniqueness of the bone microenvironment and combined with several common steps in the metastatic process, osteolytics bone metastases can be more efficiently and selectively inhibited.
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
TLDR
It is demonstrated that risedronate decreases metastatic MDA-231 breast cancer burden selectively in bone, as well as suppresses progression of established osteolytic lesions and prevents the development of new osteolytics lesions; thus, the data suggest that inhibition of osteoclastic bone resorption may be a useful adjunctive therapy for the treatment of cancers that have colonized in bone.
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti‐tumour activity
Bisphosphonates are in widespread use to prevent bone resorption in a number of metabolic and tumour‐induced bone diseases including multiple myeloma. Recent reports suggest that bisphosphonate
Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
TLDR
The previously unrecognized effect of bisphosphonates on tumor-induced osteoclastic resorption makes these agents suitable for earlier pharmacologic intervention in patients with breast cancer at risk of developing bone metastases.
Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
TLDR
Clodronate can reduce the incidence and number of new bony and visceral metastases in women with breast cancer who are at high risk for distant metastases.
Bisphosphonates and breast carcinoma
The skeleton is a common site of breast carcinoma metastasis; 75% of patients with breast carcinoma demonstrate bone metastases at autopsy. The lytic destruction of bone in these patients is due to
Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment
  • S. Derenne, M. Amiot, R. Bataille
  • Biology, Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1999
TLDR
The apoptosis of myeloma cells and BMSCs and the inhibition of both IL‐6 and MMP‐1 production induced by bisphosphonates, mainly zoledronate, could have antitumoral effects in patients with MM, but the up‐regulation of M MP‐2 secretion observed in vitro suggests a putative risk of tumor cell dissemination in vivo when using these new potent bisph phosphonates.
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
TLDR
The combined activities of alendronate and taxol appeared to inhibit the establishment and growth of tumors in SCID mice, perhaps, in part, as a result of inhibition of protease production and release.
Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.
TLDR
Findings support the hypothesis that epithelial to mesenchymal transition (EMT)-like events may be instrumental in the metastatic progression of human breast cancer and appear to have undergone the MCF-7 subline MCf-7ADR.
...
...